ÂÜÀòÂÒÂ×

Andrew Cunningham is a seasoned professional in clinical development and pharmacovigilance with extensive experience across multiple companies. Currently serving as SVP of Clinical Development at CalciMedica and as a consultant at BlueJay Consulting, LLC, Andrew has held significant leadership positions, including Vice President at Taysha Gene Therapies and Associate Vice President at Reata Pharmaceuticals, Inc. Andrew's expertise encompasses clinical development, risk management, and safety in various therapeutic areas, including neurology and oncology. With an educational background that includes an MBA from University College Dublin and a Dip Pharm Med from Trinity College Dublin, Andrew also completed an executive program at MIT Sloan School of Management.